

119TH CONGRESS
1ST SESSION

H. R. 5467

To amend title XVIII of the Social Security Act to require coverage of drugs for autoimmune diseases and certain blood disorders under Medicare part D.

IN THE HOUSE OF REPRESENTATIVES

SEPTEMBER 18, 2025

Ms. JOHNSON of Texas (for herself and Mr. KENNEDY of Utah) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned

A BILL

To amend title XVIII of the Social Security Act to require coverage of drugs for autoimmune diseases and certain blood disorders under Medicare part D.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Patient Access to
5 Autoimmune Treatments Act” or the “PAAT Act”.

1 **SEC. 2. REQUIRING COVERAGE OF DRUGS FOR AUTO-**
2 **IMMUNE DISEASES AND CERTAIN BLOOD DIS-**
3 **ORDERS UNDER MEDICARE PART D.**

4 Section 1860D–4 of the Social Security Act (42
5 U.S.C. 1395w–104) is amended—

6 (1) in subsection (b)(3), by adding at the end
7 the following new subparagraph:

8 “(J) REQUIRED INCLUSION OF CERTAIN
9 DRUGS FOR AUTOIMMUNE DISEASES AND
10 BLOOD DISORDERS.—

11 “(i) IN GENERAL.—For 2027 and
12 each subsequent year, a PDP sponsor of-
13 fering a prescription drug plan shall in-
14 clude each covered part D drug that is an
15 autoimmune or blood disorder drug de-
16 scribed in clause (ii).

17 “(ii) AUTOIMMUNE OR BLOOD DIS-
18 ORDER DRUG.—For purposes of clause (i),
19 a drug described in this clause is a covered
20 part D drug indicated and prescribed for
21 the treatment of an autoimmune disease,
22 hemophilia, or Von Willebrand disease.”;
23 and

24 (2) in subsection (c)—

25 (A) by redesignating paragraph (6), as
26 added by section 50354 of division E of the Bi-

1 partisan Budget Act of 2018 (Public Law 115–
2 123), as paragraph (7); and

3 (B) by adding at the end the following new
4 paragraph:

5 “(8) PROHIBITION ON USE OF PRIOR AUTHOR-
6 IZATION FOR CERTAIN AUTOIMMUNE OR BLOOD DIS-
7 ORDER DRUGS.—For plan years beginning on or
8 after January 1, 2027, a PDP sponsor offering a
9 prescription drug plan (and an MA organization of-
10 fering an MA–PD plan) may not require, with re-
11 spect to an individual enrolled under such plan, that
12 prior authorization for an autoimmune or blood dis-
13 order drug (as described in subsection (b)(3)(J)(ii))
14 be obtained more than once during any 12-month
15 period unless such drug is—

16 “(A) typically used for a period of 12
17 months or less;

18 “(B) an opioid, a benzodiazepine, a bar-
19 biturate, or carisoprodol; or

20 “(C) a drug with respect to which a risk
21 evaluation and mitigation strategy is required
22 under Section 505–1 of the Federal Food,
23 Drug, and Cosmetic Act.”.

○